Phase 2 Study of Lovastatin as Breast Cancer Chemoprevention
Trial ID or NCT#
NCT00285857
Status
NOT RECRUITING
Purpose
The study evaluates if a 6-month course of oral lovastatin at 80 mg/day would decrease abnormal breast duct cytology in women with a high inherited breast cancer risk.
Official Title
A Phase 2 Trial of Lovastatin for Modification of Abnormal Breast Duct Cytology and Risk-Associated Biomarkers in Women at High Inherited Risk of Breast Cancer
Eligibility Criteria
Ages Eligible for Study: 18 Years to 65 Years
Sexes Eligible for Study: FEMALE
Accepts Healthy Volunteers: No
Investigator(s)
Allison W. Kurian, M.D., M.Sc.
Medical oncologist,
Breast specialist,
Cancer geneticist
Professor of Medicine (Oncology) and of Epidemiology and Population Health
Contact us to find out if this trial is right for you.
Contact
Meredith Mills
6507245223
View on ClinicalTrials.gov
